Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.

Journal of viral hepatitis - 1 Oct 2016

Deuffic-Burban S, Obach D, Canva V, Pol S, Roudot-Thoraval F, Dhumeaux D, Mathurin P, Yazdanpanah Y

Abstract excerpt

We evaluated the cost-effectiveness and the budget impact of new DAA-based regimen use in France. A Markov model simulated chronic hepatitis C (CHC) treatment interventions with IFN-based and IFN-free regimens at stage of fibrosis ≥F3, ≥F2 or regardless of fibrosis stage, and treatment either with the least or the most expensive combination. It estimated quality-adjusted life years (QALYs) and incremental...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Sectional Studies

Share to France

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Protease Inhibitors

Share to Quality-Adjusted Life Years

Source

Identifiers

PMID: 27144512
DOI: 10.1111/jvh.12546

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.PMID 27144512Read ↗

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read ↗

Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil.Semantic proximity Read ↗

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.Semantic proximity Read ↗

The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.Semantic proximity Read ↗

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.Semantic proximity Read ↗

Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.Semantic proximity Read ↗

Real-world value of direct-acting antivirals for hepatitis C at Kaiser Permanente Southern California.Semantic proximity Read ↗

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study.Semantic proximity Read ↗

Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.Semantic proximity Read ↗

Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.Semantic proximity Read ↗

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.Semantic proximity Read ↗

Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.